Gözde YILDIRIM ÇETİN, Ayşe BALKARLI, Nurhan ATİLLA

Association of neutrophil/lymphocyte ratio with the degree of interstitial lung disease in systemic sclerosis

Background/aim: Determining the severity of systemic sclerosis related interstitial lung disease (SSc-ILD) is based on clinical and radiological findings, inflammation marker levels, and carbon monoxide diffusing capacity of the lung (DLCO). Recently studies are ongoing for objective and easy markers. Neutrophil/lymphocyte ratio (NLR) is shown to be a good marker for inflammation in recent clinical trials. In this study, we aimed to identify the possible relationship between NLR and carbon monoxide transfer coefficient (KCO) of SSc-ILD patients. Materials and methods: Fifty-nine patients with systemic sclerosis (SSc) were enrolled in the study. We used high-resolution computed tomography for diagnosis and used DLCO to evaluate degree of lung involvement. Complete blood cell counts and acute phase reactants were included as laboratory assessments. Results: NLR values were significantly higher in the SSc-ILD group (3.66 ± 1.32 vs. 2.85 ± 1.12, P = 0.01) and correlated negatively with KCO. The NLR cut-off value was 3.21, its sensitivity was 81%, and its specificity was 81%. Conclusion: NLR level may serve as a marker of lung involvement in the presence of ILD in patients with SSc.

PDF

___

1. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202.
2. King TE Jr, Kim EJ, Kinder BW. Connective tissue diseases. In: Schwartz MI, King TE Jr, editors. Interstitial Lung Disease. 5th ed. Shelton, CT, USA: Peoples Medical Publishing House; 2011. pp. 689.
3. Muangchan C, Harding S, Khimdas S, Bonner A, Canadian Scleroderma Research group, Baron M, Pope J. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res 2012; 64: 1405-1414.
4. Absenger G, Szkandera J, Pichler M, Stotz M, Arminger F, Weissmueller M, Schaberl-Moser R, Samonigg H, Stojakovic T, Gerger A. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer 2013; 109: 395-400.
5. Kırkıl G. İnterstisyel akciğer hastalığında solunum fonksiyon testlerinin tanı ve hastalık monitorizasyonundaki rolü nedir? Güncel Göğüs Hastalıkları Serisi 2014; 2: 313-319 (in Turkish).
6. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, Haslam PL, Vassilakis DA, Black CM, du Bois RM. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581-1586.
7. Wells AU, Hansell DM, Rubens MB, King AD, Cramer D, Black CM, du Bois RM. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 1997; 40: 1229-1236.
8. Pastre J, Plantier L, Planes C, Borie R, Nunes H, Delclaux C, Israël-Biet D. Different KCO and VA combinations exist for the same DLCO value in patients with diffuse parenchymal lung diseases. BMC Pulm Med 2015; 15: 100.
9. Mortensen RF. C-reactive protein, inflammation, and innate immunity. Immunol Res 2001; 24: 163-176.
10. Bryan C, Knight C, Black CM, Silman AJ. Prediction of five year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42: 2660-2665.
11. Czirjak L, Kumanovics G, Varju C, Nagy Z, Pákozdi A, Szekanecz Z, Szűcs G. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008; 67: 59-63.
12. Ohtsuka T. Relation between elevated high-sensitivity C-reactive protein and anti-mitochondria antibody in patients with systemic sclerosis. J Dermatol 2008; 35: 70-75.
13. Ohtsuka T. Serum interleukin-6 level is reflected in elevated high-sensitivity C-reactive protein level in patients with systemic sclerosis. J Dermatol 2010; 37: 801-806.
14. Jager CP, van Wijk PT, Mathoera RB, de Jongh-Leuvenink J, van der Poll T, Wever PC. Lymphocytopenia and neutrophillymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit. Crit Care 2010; 14: 192.
15. Polat N, Yildiz A, Yuksel M, Bilik MZ, Aydin M, Acet H, Akil MA, Oylumlu M, Kaya H, Ertas F et al. Association of neutrophil-lymphocyte ratio with the presence and severity of rheumatic mitral valve stenosis. Clin Appl Thromb Hemost 2014; 20: 793-798.
16. Ohno Y, Nakashima J, Ohori M, Gondo T, Hatano T, Tachibana M. Follow up of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol 2012; 187: 411-417.
17. Shah N, Parikh V, Patel N, Patel N, Badheka A, Deshmukh A, Rathod A, Lafferty J. Neutrophil lymphocyte ratio significantly improves the Framingham risk score in prediction of coronary heart disease mortality: Insights from the National Health and Nutrition Examination Survey-III. Int J Cardiol 2014; 171: 390-397.
18. Tekeoglu I, Gurol G, Harman H, Karakece E, Ciftci IH. Overlooked hematological markers of disease activity in rheumatoid arthritis. International Journal of Rheumatic Diseases, 2015 doi: 10.1111/1756-185X.12805. [Epub ahead of print].
19. Celikbilek M, Dogan S, Ozbakır O, Zararsız G, Kücük H, Gürsoy S, Yurci A, Güven K, Yücesoy M. Neutrophillymphocyte ratio as a predictor of disease severity in ulcerative colitis. J Clin Lab Anal 2013; 27: 72-76.